Table of Contents
Chemotherapy Research and Practice
Volume 2011, Article ID 163736, 6 pages
http://dx.doi.org/10.1155/2011/163736
Case Report

A Regimen of Taxol, Ifosfamide, and Platinum for Recurrent Advanced Squamous Cell Cancer of the Anal Canal

1The Ohio State University Medical Center, 395 West 12th Avenue, 3rd Floor, Columbus, OH 43210, USA
2Department of Radiology, University of Louisville, 530 South Jackson Street, Suite C07, Louisville, KY 40202, USA
3University of Louisville, James Graham Brown Cancer Center, 529 South Jackson Street, Louisville, KY 40202, USA

Received 14 January 2011; Accepted 18 April 2011

Academic Editor: Vito Lorusso

Copyright © 2011 Diana V. Golub et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The typically recommended chemotherapy options in metastatic anal cancer generally yield partial remissions with limited benefit for the majority of patients. TIP is a regimen containing paclitaxel (Taxol), ifosfamide, and cisplatin that is known to have significant activity in patients with squamous cell cancers of the head and neck as well as in cervical cancer, both of which are malignancies strongly associated with oncogenic strains of human papilloma virus (HPV). Interestingly, squamous cell cancer of the anal canal shares an almost identical pathophysiology including causal association with HPV. Due to this, we chose to use the TIP regimen to treat patients with advanced anal cancer at our institution and report our findings on three such consecutive patients. All the patients tolerated the regimen well with manageable side effects and had excellent responses with complete resolution of PET activity after treatment. Our observations suggest that TIP is highly active for squamous cell cancer of the anal canal and warrants further study in the treatment of this disease.